{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T02:54:33Z","timestamp":1675220073725},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/ppo.0b013e31826dc00b","type":"journal-article","created":{"date-parts":[[2012,9,21]],"date-time":"2012-09-21T21:40:28Z","timestamp":1348263628000},"page":"427-431","source":"Crossref","is-referenced-by-count":4,"title":["Autotransplantation for Mantle Cell Lymphoma"],"prefix":"10.1097","volume":"18","author":[{"given":"Julie M.","family":"Vose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210203","first-page":"405","article-title":". Classification of non-Hodgkins lymphomas.","volume":"2","author":"Gerard-Marchant","year":"1974","journal-title":"Lancet"},{"key":"R3-8-20210203","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":". Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network.","volume":"131","author":"Tiemann","year":"2005","journal-title":"Br J Hematol"},{"key":"R4-8-20210203","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":", How I. treat Mantle cell lymphoma.","volume":"114","author":"Ghielmini","year":"2009","journal-title":"Blood"},{"key":"R5-8-20210203","first-page":"329","article-title":". Mantle cell lymphoma: a retrospective study of 121 cases.","volume":"34","author":"Samaha","year":"1998","journal-title":"Leukemia"},{"key":"R6-8-20210203","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkins lymphoma.","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"R7-8-20210203","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":". A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma.","volume":"11","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"R8-8-20210203","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":". Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"},{"key":"R9-8-20210203","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":". Improvement of overall survival in advanced stage mantle cell lymphoma.","volume":"27","author":"Herrmann","year":"2008","journal-title":"J Clin Oncol"},{"key":"R10-8-20210203","first-page":"640","article-title":". Autologous hematopoietic stem cell transplantation for mantle cell lymphoma.","volume":"6","author":"Vose","year":"2000","journal-title":"BBMT"},{"key":"R11-8-20210203","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdi107","article-title":". Hematopoietic stem cell transplantation in mantle cell lymphoma.","volume":"16","author":"Ganti","year":"2005","journal-title":"Ann Oncol"},{"key":"R12-8-20210203","first-page":"39","article-title":". Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.","volume":"11","author":"Kasamon","year":"2005","journal-title":"BBMT"},{"key":"R13-8-20210203","first-page":"18a","article-title":". Outcome of patients with mantle cell lymphoma undergoing autologous versus reduced intensity allogeneic transplantation.","volume":"22","author":"Fenske","year":"2011","journal-title":"Ann Oncol"},{"key":"R14-8-20210203","first-page":"38a","article-title":". Allogeneic transplantation (alloHCT) for patients with mantle cell lymphoma (MCL) progressing after autologous transplantation (autoHCT). On behalf of the writing committee, Center for International Blood and Marrow Transplantation Research (CIBMTR).","volume":"22","author":"Hari","year":"2011","journal-title":"Ann Oncol"},{"key":"R15-8-20210203","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":". High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"key":"R16-8-20210203","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2008.19.2245","article-title":". Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkins lymphoma.","volume":"27","author":"Winter","year":"2009","journal-title":"J Clin Oncol"},{"key":"R17-8-20210203","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","article-title":". Phase II trial of transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkins lymphoma.","volume":"26","author":"Krishnana","year":"2008","journal-title":"J Clin Oncol"},{"key":"R18-8-20210203","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1200\/JCO.2005.05.117","article-title":". Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkins lymphoma.","volume":"23","author":"Vose","year":"2005","journal-title":"J Clin Oncol"},{"key":"R19-8-20210203","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":". Hyper-CVAD and high-dose methotrexatecytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"R20-8-20210203","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2141.2007.06908.x","article-title":". A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow up in newly diagnosed mantle cell lymphoma.","volume":"140","author":"Evens","year":"2008","journal-title":"Br J Haematol"},{"key":"R21-8-20210203","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":". Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"R22-8-20210203","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3324\/haematol.10608","article-title":". Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.","volume":"92","author":"Dreger","year":"2007","journal-title":"Haematologica"},{"key":"R23-8-20210203","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":". Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"R24-8-20210203","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":". Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"R25-8-20210203","first-page":"249a","article-title":". The addition of stem cell transplantation following induction chemotherapy improves overall survival in mantle cell lymphoma patients who achieve a complete response.","volume":"27","author":"Vose","year":"2012","journal-title":"Proc Eur Hematol Assoc"},{"key":"R26-8-20210203","doi-asserted-by":"crossref","first-page":"387a","DOI":"10.1182\/blood.V110.11.387.387","article-title":". A multi-center trial of hyperCVAD rituxan in patients with newly diagnosed mantle cell lymphoma.","volume":"110","author":"Epner","year":"2007","journal-title":"Blood"},{"key":"R27-8-20210203","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":". Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.","volume":"17","author":"Kahl","year":"2006","journal-title":"Ann Oncol"},{"key":"R29-8-20210203","doi-asserted-by":"crossref","first-page":"110a","DOI":"10.1182\/blood.V116.21.110.110","article-title":". Alternating courses of 3X CHOP and 3X DHAP plus rituximab followed by a high-dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the European Mantle Cell Lymphoma Network.","volume":"116","author":"Hermine","year":"2010","journal-title":"Blood"},{"key":"R30-8-20210203","first-page":"234a","article-title":". High dose Aracytine in induction might counteract the adverse prognostic value of gene copy number alternation in autografted MCL patients. A EUMCL Network Study.","volume":"22","author":"Delfau-Larue","year":"2011","journal-title":"Ann Oncol"},{"key":"R31-8-20210203","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":". Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"R32-8-20210203","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":". Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol"},{"key":"R33-8-20210203","doi-asserted-by":"crossref","first-page":"3a","DOI":"10.1200\/jco.2012.30.15_suppl.3","article-title":". Bendamustine plus rituximab (BR) versus CHOP plus rituximab (CHOP-R) as first line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study.","volume":"30","author":"Rummel","year":"2012","journal-title":"J Clin Oncol"},{"key":"R34-8-20210203","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":". Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 Pinnacle study.","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"R35-8-20210203","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.leu.2404959","article-title":". Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.","volume":"22","author":"Wang","year":"2008","journal-title":"Leukemia"},{"key":"R36-8-20210203","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1078-0432.CCR-09-1937","article-title":". Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.","volume":"16","author":"Paoluzzi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R37-8-20210203","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","article-title":". The combination of bendamustine, bortezomib, and rituximab for patients with relapsedrefractory indolent and mantle cell non-Hodgkin lymphoma.","volume":"117","author":"Friedberg","year":"2011","journal-title":"Blood"},{"key":"R38-8-20210203","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":". Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"key":"R39-8-20210203","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1200\/JCO.2008.20.7977","article-title":". Phase III study to evaluate temsirolimus compared with investigators choice therapy for the treatment of relapsed refractory mantle cell lymphoma.","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"R41-8-20210203","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":". Mechanism of action of lenalidomide in hematological malignancies.","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"key":"R42-8-20210203","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":". Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"R43-8-20210203","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":". Antitumor activity of rituximab plus thalidomide in patients with relapsedrefractory mantle cell lymphoma.","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"key":"R44-8-20210203","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":". Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"R45-8-20210203","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":". An international phase II trial of single agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkins lymphoma.","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"R46-8-20210203","first-page":"109a","article-title":". Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in relapsedrefractory mantle cell lymphoma: a completed phase III clinical trial.","volume":"22","author":"Wang","year":"2011","journal-title":"Ann Oncol"},{"key":"R47-8-20210203","first-page":"153a","article-title":". The BTK inhibitor PCI-32765 is highly active and well tolerated in patients (pts) with relapsedrefractory B cell malignancies: final results from a phase I study.","volume":"22","author":"Advani","year":"2011","journal-title":"Ann Oncol"},{"key":"R48-8-20210203","first-page":"350a","article-title":". Significant clinical activity of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3 kinase P110D, in patients with relapsed or refractory indolent and mantle cell lymphoma.","volume":"22","author":"Kahl","year":"2011","journal-title":"Ann Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0b013e31826dc00b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:26:49Z","timestamp":1620970009000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201209000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0b013e31826dc00b","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}